BioCentury | Dec 20, 1999
Clinical News

Esprolol: Phase IIb

...Selectus said it will seek a partner to conduct Phase III testing of the product. Selectus Pharmaceuticals Inc....
BioCentury | Jun 28, 1999
Clinical News

Esprolol: Began Phase IIb study

...category: Receptor antagonist Target: Beta adrenergic receptors Description: Sublingual beta-blocker Indication: Treat angina pectoris Status: Selectus...
BioCentury | Dec 7, 1998
Clinical News

Esprolol sublingual beta blocker: Phase I and II data; Phase II

...showed beta blockade, with a 20 percent average decrease in peak heart rate after treatment. Selectus Pharmaceuticals Inc....
BioCentury | Jan 27, 1997
Finance

Proof of principle investing

...be sold, according to Broderson. The fund is starting with a portfolio of three companies: Selectus Pharmaceuticals Inc....
...on Alzheimer's disease. Both Selectus and Latis expect to begin clinical trials within a year. Selectus...
...glaucoma and asthma. In angina, the company is developing sublingually delivered beta blockers. In glaucoma, Selectus...
Items per page:
1 - 4 of 4
BioCentury | Dec 20, 1999
Clinical News

Esprolol: Phase IIb

...Selectus said it will seek a partner to conduct Phase III testing of the product. Selectus Pharmaceuticals Inc....
BioCentury | Jun 28, 1999
Clinical News

Esprolol: Began Phase IIb study

...category: Receptor antagonist Target: Beta adrenergic receptors Description: Sublingual beta-blocker Indication: Treat angina pectoris Status: Selectus...
BioCentury | Dec 7, 1998
Clinical News

Esprolol sublingual beta blocker: Phase I and II data; Phase II

...showed beta blockade, with a 20 percent average decrease in peak heart rate after treatment. Selectus Pharmaceuticals Inc....
BioCentury | Jan 27, 1997
Finance

Proof of principle investing

...be sold, according to Broderson. The fund is starting with a portfolio of three companies: Selectus Pharmaceuticals Inc....
...on Alzheimer's disease. Both Selectus and Latis expect to begin clinical trials within a year. Selectus...
...glaucoma and asthma. In angina, the company is developing sublingually delivered beta blockers. In glaucoma, Selectus...
Items per page:
1 - 4 of 4